Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 6/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 5/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843639 | 0.98 | FABP4 (0.38) | FABP4FABP5ABL1DGAT2PIK3CA | |
| Lithium SCHEMBL1842444 | 0.92 | ABL1 (0.40) | ABL1PIK3CAPIK3CG | |
| Lithium Ion SCHEMBL1843643 | 0.92 | ABL1 (0.38) | ABL1DGAT2PIK3CAPIK3CG | |
| SCHEMBL1842429 | 0.91 | ABL1 (0.40) | ABL1PIK3CAPIK3CG | |
| Lithium SCHEMBL1842713 | 0.88 | ABL1 (0.41) | FABP4FABP5ABL1PIK3CAPIK3CG | |
| SCHEMBL2181072 | 0.88 | PLAU (0.39) | FABP4ABL1DGAT2 | |
| SCHEMBL1843794 | 0.88 | ABL1 (0.47) | ABL1 | |
| SCHEMBL4540026 | 0.87 | ABL1 (0.41) | FABP4FABP5ABL1PIK3CAPIK3CG | |
| SCHEMBL1842700 | 0.87 | ABL1 (0.41) | FABP4FABP5ABL1PIK3CAPIK3CG | |
| SCHEMBL1843004 | 0.86 | MAPK1 (0.43) | ABL1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | claimed |
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | disclosed |
| EP-2321309-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009156966-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | TOP2B, TOP1, POLI | FABP4 2999/4885FABP5 3070/4885ABL1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.